DIRS.INFO The most relevant business & tech news

☆ Mark Cuban's online pharmacy set to launch Humira biosimilar
▼ + stars: | 2023-07-05 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

July 5 (Reuters) - Mark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences's (CHRS.O) biosimilar version of AbbVie Inc's (ABBV.N) blockbuster rheumatoid arthritis drug Humira, Cuban said on Wednesday. Cost Plus Drugs will sell Yusimry for $569.27 plus dispensing and shipping fees. Coherus introduced its Humira biosimilar in the U.S. market this month alongside offerings from other drugmakers such as Boehringer Ingelheim, Sandoz and Organon (OGN.N). Cuban's Cost Plus Drugs aims to drive down the cost of drugs broadly by selling them at a 15% markup over its cost, plus pharmacy fees. Cuban said the company hopes to provide other biosimilar drugs as well.

Persons: Humira, Cuban, Coherus, AbbVie, Michael Erman, David Holmes Organizations: Cuban, Plus, Sandoz, Cuban's, Thomson Locations: U.S, Organon, Cuban

☆ The options for weight loss treatment are about to explode. These are the companies investors need to know
▼ + stars: | 2023-07-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +14 min

Wegovy was approved as an obesity treatment in June 2021 , but Ozempic, a Type 2 diabetes treatment, has been used off-label for weight loss. Mounjaro uses GLP-1 and gastric inhibitory polypeptide, or GIP, to help patients lose weight. Eli Lilly's oral drug, orforglipron, has an even better profile . They also could be helpful in assisting patients in maintaining weight loss after they've used the injectable versions, he said. Some have highlighted that oral drugs also may be more manageable for patients who can't handle the idea of giving themselves a once-a-week injection.

Persons: Eli Lilly, we're, Jonathan Wolleben, Wegovy, Lilly's tirzepatide, It's, Mounjaro, Wolleben, Eli Lilly's tirzepatide, Lilly, —, Novo, Eli, it's, they've, FactSet, Altimmune's pemvidutide, Morgan Stanley, Mark Purcell, Purcell, Graig Suvannavejh, Suvannavejh, Roth, Dylan Dupuis, Dupuis, Trung Huynh, Goldman Sachs, Chris Shibutani, Shibutani Organizations: Novo Nordisk, JMP Securities, Citizens Company, Nordisk's Ozempic, Food and Drug Administration, Nordisk, Novo, Zealand Pharma, Shandong Suncadia, GSBR, Biosciences, Fujian Shengdi Pharmaceutical, Mizuho Securities, Terns Pharmaceuticals, American Diabetes Association, Viking Therapeutics, Pfizer, Credit Suisse, AstraZeneca, Therapeutics, Medicare, Medicaid, CNBC Pro's Locations: Danish, Shandong, Fujian, Viking

☆ Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
▼ + stars: | 2023-07-03 | by ( ) www.reuters.com time to read: +1 min

July 3 (Reuters) - Coherus BioSciences (CHRS.O) said on Monday it has launched a copycat version of AbbVie's (ABBV.N) Humira in the United States at a discount of more than 85% to the blockbuster arthritis drug. Coherus is the latest to launch a biosimilar to Humira in the U.S. market this month after Boehringer Ingelheim, Sandoz and Organon (OGN.N). Coherus said last month it would sell the biosimilar, branded as Yusimry, at $995 per carton, compared with the current list price of Humira of $6,922 per carton. The company has also partnered with billionaire entrepreneur Mark Cuban's pharmaceutical startup to sell the biosimilar at $569.27 plus dispensing and shipping fees. Usually prices fall, often dramatically, when multiple copycat versions of a widely-used medication enter the market.

Persons: Coherus, Boehringer Ingelheim, Mark, Sriparna Roy, Leroy Leo, Shounak Dasgupta, Arun Koyyur Organizations: Coherus BioSciences, Sandoz, Thomson Locations: United States, Humira, U.S, Organon, Bengaluru

☆ Controversial Chinese scientist He Jiankui proposes new gene editing research
▼ + stars: | 2023-07-03 | by ( Simone Mccarthy | ) edition.cnn.com time to read: +8 min

Authorities in China took multiple steps to tighten rules and ethical standards affecting human gene editing in the wake of the revelations about his previous research. But the scientist’s release of a new proposal involving gene editing of embryos has scientists and medical ethics experts concerned – and confused. Genetic manipulation of human embryos – both viable and nonviable ones – is typically tightly controlled globally and some countries ban all such research, experts say. But there is robust global debate around allowing genome editing of human embryos to treat serious genetic conditions or expanding research. Chinese law does not allow gene-edited human embryos used in research to be implanted into humans, or developed for more than 14 days.

Persons: ”, It’s, Peter Dröge, “, “ I’m, ” Joy Zhang, bioethicists, There’s, He’s, He’s “, Françoise Baylis, ” Baylis Organizations: Hong Kong CNN, Authorities, Nanyang Technological University, Centre for Global Science, University of Kent, CNN, bioethicists, Twitter, China’s Ministry of Science, Technology, National Health Commission, Southern University of Science, China’s biosciences, Dalhousie University Locations: Hong Kong, China, Beijing, Singapore, Britain, USA, Europe, Shenzhen

☆ 24 'strong-buy' stocks with the highest potential upsides based on consensus price targets from Wall Street's top-performing analysts, according to a fintech company
▼ + stars: | 2023-07-02 | by ( Laila Maidan | ) www.businessinsider.com time to read: +1 min

TipRanks compiles stocks that Wall Street's top analysts agree are strong buys. These 24 stocks have the highest upsides, based on averages of the top analysts' price targets. This year's stock market outlook remains uncertain even after a return to a bull market in the second quarter. The bond market is signaling a recession because of an inverted yield curve, while a strong jobs market and rallying stock market are pointing to strength. TipRanks, a fintech company that compiles and analyzes stock-market data, curates a list of the stocks most loved by top analysts.

Persons: Michael Cuggino, Gary Black Organizations: Biosciences, Wall

☆ Stocks making the biggest moves midday: Apple, Meta Platforms, Carnival, Nike and more
▼ + stars: | 2023-06-30 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

In this photo illustration, the 2023 Apple Worldwide Developers Conference (WWDC 23) logo is displayed on a smartphone screen. Check out the companies making headlines in midday trading Friday. Citi also slapped a $240 price target on the stock, the highest on the Street. SolarEdge — The solar stock rose 3.3% after Bank of America raised its price target to $396 from $379. Bright Health Group — Shares added 2.6% in midday trading after the health insurer announced a deal to sell its California Medicare Advantage business to Molina Healthcare for roughly $600 million.

Persons: Goldman Sachs, Xpeng, —, Alex Harring, Tanaya Macheel, Sarah Min Organizations: Developers, Apple —, Citi, Journal, SEC, BlackRock, Pacific Biosciences, Bank of America, Bright Health, Molina Healthcare, Nike —, Nike, Markets Authority, Jefferies Locations: Thursday's, California

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Carnival, Snowflake, Nike, SolarEdge and more
▼ + stars: | 2023-06-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Jefferies upgrades Carnival to buy from hold Jefferies said it sees a "confluence of positive dynamics" for Carnival. Citi initiates Apple as buy Citi said it sees further upside for the tech giant, slapping a Street-high $240 price target. Citi initiates Dell as buy Citi said the computer maker is gaining share. Goldman Sachs reiterates Nike as buy Goldman Sachs said it's standing by shares of Nike after the company's earnings report Thursday. " Bank of America reiterates T-Mobile as buy Bank of America said the stock is "undervalued."

Persons: TD Cowen, Cowen, Goldman Sachs, Goldman, Jefferies, Snowflake, Virgin, Daiwa, NKE, Stephens, SolarEdge, Riley, Stifel, Davidson Organizations: Citi, Pacific Biosciences, Pacific Bioscience, Jefferies, Deutsche Bank, Apple, Dell, Bank of America, Virgin Galactic, underperform Bank of America, Virgin Galactic's, Italian Air Force, AMD, Intel, Nike, BMO, FirstService Brands, Occidental Petroleum, Mobile, Southwestern Energy Locations: 3Q23, China, Occidental, midstream

☆ Bayer claims early lead in Parkinson's stem cell therapy
▼ + stars: | 2023-06-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

Some of this work is done by Britain's' Cambridge University, South Korea's Bundang CHA Hospital, International Stem Cell Corp's (ISCO.PK) Cyto Therapeutics in Australia, the Chinese Academy of Sciences, Harvard University and Japan's Kyoto University Hospital. For BlueRock's experimental therapy, researchers took induced pluripotent stem cells, which are modified to regain the ability to form any type of specialised tissue, and transformed them into dopamine-producing nerve cells. When surgically implanted into the brain of a person with Parkinson's disease, the therapeutic cells are designed to restore neural networks destroyed by the disease. Initial trial results showed the cells multiplied and started making dopamine, an important brain signalling molecule which is lacking in Parkinson's patients. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.

Persons: Wolfgang Rattay, Bayer, BlueRock, Britain's, Jennifer Doudna, Ludwig Burger, Miranda Murray, Mark Potter Organizations: Bayer AG, REUTERS, Bayer, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, BlueRock Therapeutics, Mammoth Biosciences, Thomson Locations: Leverkusen, Germany, FRANKFURT, Australia, San Francisco Bay

☆ The North Atlantic is experiencing a ‘totally unprecedented’ marine heat wave
▼ + stars: | 2023-06-20 | by ( Laura Paddison | ) edition.cnn.com time to read: +4 min

CNN —Temperatures in parts of the North Atlantic Ocean are soaring off the charts, with an “exceptional” marine heat wave happening off the coasts of the United Kingdom and Ireland, sparking concerns about impacts on marine life. Parts of the North Sea are experiencing a category 4 marine heat wave – defined as “extreme” – according to the National Oceanic and Atmospheric Administration. And in 2021, an extreme heat wave cooked around a billion shellfish to death on Canada’s West Coast. As climate change intensifies, marine heat waves are set to become more common. The frequency of marine heat waves has already increased more than 20-fold due to human-caused global warming, according to a 2020 study.

Persons: ” Stephen Belcher, ”, Mika Rantanen, Richard Unsworth, “, ” Unsworth, Albert Klein Tank, Rantanen Organizations: CNN, National Oceanic, Atmospheric Administration, UK Met, Met Office’s, Finnish Meteorological Institute, biosciences, Plymouth University, UK Met Office, Met Office Hadley Locations: United Kingdom, Ireland, Iceland, Europe, Gulf Coast, Texas, West Coast, El

☆ Chris Christie's appeal with moderates and previous ties to Trump helped make him the 'George Washington' of sports betting, former lobbyist said
▼ + stars: | 2023-06-18 | by ( Hannah Getahun | ) www.businessinsider.com time to read: +4 min

His ties to former Donald Trump helped foster relationships with companies, per the Times. One such company was sports betting site DraftKings, the Times reported. Christie asserts that his time working with the company did not overlap with his time working with Trump. Sports betting companies like DraftKings also paid Christie thousands to advise and lobby their interests. One unnamed source told the outlet that one company, Scientific Games, paid Christie $30,000 a month as a consultant in 2018.

Persons: Chris Christie, Donald Trump, —, Christie, DraftKings, Jeremy Kudon, Trump, George Washington, Kudon, Trump's Organizations: New York Times, Times, Service, Pacira Biosciences, Trump, Trump . Sports, Sports, Hall of Fame, Scientific, Scientific Games Locations: New Jersey

☆ The Business of Being Chris Christie
▼ + stars: | 2023-06-16 | by ( Nick Corasaniti | Alexandra Berzon | ) www.nytimes.com time to read: +1 min

And in 2018, the Christies bought a multimillion-dollar shorefront home in Bay Head, one of the more exclusive towns on the Jersey Shore. The business of being Chris Christie has received only sporadic attention since he left public office. Mr. Christie has made millions from interests wanting to leverage his political ties, including pharmaceutical, medical and sports betting companies, like DraftKings — whose hiring of Mr. Christie has not been previously reported. Some had business with the state when Mr. Christie was governor, and saw him as a reliable advocate for their bottom line, while others were interested in tapping into his close association with Mr. Trump and the Trump administration. Christie 55 Solutions earned roughly $1.3 million in federal lobbying fees from April 2020 to April 2021, according to federal records.

Persons: Bon Jovi, Chris Christie, Donald J, Trump, —, Christie, DraftKings Organizations: New, Mr, Christie, Pacira Biosciences, ABC News Locations: Bay Head, Jersey Shore, New Jersey

☆ A stock trader who returned 630% in 3 years and taught traders who became millionaires shares the top 3 patterns he plays daily
▼ + stars: | 2023-06-10 | by ( Laila Maidan | ) www.businessinsider.com time to read: +11 min

That year, the stock market was making headlines due to investors' excitement about internet companies. He wanted to bet on the stock market with his Bar Mitzvah money of roughly $12,000. At the time, there was no pattern day trading rule, which meant he didn't need a minimum of $25,000 to day trade. "My best-performing strategy right now is over the weekend because the stock market is closed over the weekend. The uneasiness that comes with having an income pegged to the stock market never goes away.

Persons: Timothy Sykes, Sykes, Norman Zadeh, Jack Kellogg, Kyle Williams, it's, Roe, Wade Organizations: United States, Evofem Biosciences, Tesoro Enterprises, Stocks, Cilantro, Partners, Wall Street Warriors Locations: Illinois

☆ Cancer drugmakers rise as industry meet fuels investor interest
▼ + stars: | 2023-06-05 | by ( ) www.reuters.com time to read: +2 min

June 5 (Reuters) - Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago. ImmunoGen Inc's experimental drug, Elahere, to treat a type of ovarian cancer showed 35% reduction in the risk of tumor progression or death compared to chemotherapy in a late-stage study. Shares of Evaxion rose 5.4% to $1.55 after the smaller drug developer said its vaccine to prevent a type of skin cancer met safety goals in an early-stage study. Shares of Blueprint Medicines Corp (BPMC.O) fell 9.4% to $52.76 after analysts flagged potential safety issues about its experimental drug to treat a type of lung cancer. Reporting by Manas Mishra and Mariam Sunny in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

Persons: William Blair, Manas Mishra, Mariam Sunny, Shailesh Organizations: Immunogen Inc, Evaxion, Therapeutics, American Society of Clinical Oncology, Arcus, Medicines Corp, Thomson Locations: Chicago, Bengaluru

☆ Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
▼ + stars: | 2023-05-17 | by ( David Carnevali | ) www.reuters.com time to read: +4 min

Even shares of drug companies that do not have pending deals but are seen by analysts and investors as potential acquisition targets were hit. FTC officials did not respond to a request for comment on whether they planned to challenge any other pharmaceutical acquisitions. "We could see similar challenges to the Pfizer/Seagen deal" BMO analysts wrote in a note, arguing that the FTC could target other major drug companies with the resources to engage in bundling. UNDER THE RADARConversely, investors and analysts are hoping that smaller pharmaceutical acquisitions will continue to fly under the radar of regulators. Reporting by David Carnevali in New York; Editing by Greg Roumeliotis and Jamie FreedOur Standards: The Thomson Reuters Trust Principles.

☆ Inside OpenAI's Sam Altman's fixation on death and the apocalypse
▼ + stars: | 2023-05-03 | by ( Melia Russell | Julia Black | ) www.businessinsider.com time to read: +3 min

Sam Altman, the CEO of OpenAI, spends a lot of time thinking about risk, especially as it relates to AI. One investor friend told Insider that Altman became even more fixated on delaying death when his father died in 2018. One investor friend told Insider that Altman "says we vastly underestimate risk in society." The investor friend told Insider that urgency grew when Altman's father, a real-estate developer, died in 2018. "I don't think anyone can lose your dad young and wish he didn't have more time with him," Altman told Insider.

☆ Astellas Pharma buys Iveric Bio for $5.9 billion
▼ + stars: | 2023-05-01 | by ( ) www.reuters.com time to read: +1 min

May 1 (Reuters) - Japan's Astellas Pharma (4503.T) said on Monday it agreed to buy U.S.-based drugmaker IVERIC Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. Through Berry Merger Sub Inc, a wholly-owned subsidiary of Astellas U.S. Holding, the Japanese company agreed to acquire IVERIC for $40 per share in cash, Astellas said in a release. The acquisition price is a 22% premium to IVERIC's $32.89 closing price on April 28. Prior to that, its biggest ever acquisition was its $3.8 billion purchase of OSI Pharmaceuticals Inc in 2010. Reporting by Baranjot Kaur in Bengaluru; Editing by Kim CoghillOur Standards: The Thomson Reuters Trust Principles.

☆ Merck revenue falls after dramatic drop in sales of Covid antiviral treatment
▼ + stars: | 2023-04-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Merck on Thursday reported first-quarter revenue that fell 9% from the same period a year ago largely due to a steep drop in sales of its Covid antiviral treatment molnupiravir. Sales of molnupiravir plunged to $392 million during the period, down 88% from the $3.2 billion reported in the first quarter of 2022. Merck said the decrease is primarily the result of lower sales in the U.S., U.K., Japan and Australia. The company reported total revenue of $14.5 billion during the quarter, down nearly $1.5 billion from the same period a year ago. But Merck's pharmaceutical unit saw higher sales of the blockbuster antibody treatment Keytruda, which increased 20% to $5.8 billion during the quarter.

☆ Merck earnings better-than-expected on Keytruda, Gardasil strength
▼ + stars: | 2023-04-27 | by ( ) www.reuters.com time to read: +2 min

April 27 (Reuters) - Drugmaker Merck & Co on Thursday posted better-than-expected first-quarter results on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil. Sales of Keytruda rose 20% to $5.8 billion in the quarter, topping the average analyst forecast of $5.6 billion. Gardasil sales rose 35% to $2 billion, beating analyst estimates of $1.7 billion. It forecast 2023 sales of $57.7 billion to $58.9 billion, up from its previous forecast of $57.2 billion to $58.7 billion. The company reported nearly $21 billion in Keytruda sales last year.

☆ Sam Altman is building his utopia, whether you want it or not
▼ + stars: | 2023-04-27 | by ( Melia Russell | Julia Black | ) www.businessinsider.com time to read: +41 min

Altman told Insider, "We debate our approach frequently and carefully." "I don't think anyone can lose your dad young and wish he didn't have more time with him," Altman told Insider. Altman told Insider that his thinking had evolved since those posts. (When asked about guns, Altman told Insider he'd been "happy to have one both times my home was broken into while I was there.") When asked about this, Altman told Insider in an email: "i can guess what that's about; these stories grow crazily inflated over the years of getting re-told!

☆ He's played chess with Peter Thiel, sparred with Elon Musk and once, supposedly, stopped a plane crash: Inside Sam Altman's world, where truth is stranger than fiction
▼ + stars: | 2023-04-27 | by ( Melia Russell | Julia Black | ) www.businessinsider.com time to read: +41 min

But, "you do at some point need to start having contact with reality," he told Insider. The plan was still only a rough sketch, Blania told Insider, but that didn't seem to matter to his host. "He always wanted to understand everything at a very deep level," Thrun told Insider in an email. (When asked about guns, Altman told Insider he'd been "happy to have one both times my home was broken into while I was there.") When asked about this, Altman told Insider in an email: "i can guess what that's about; these stories grow crazily inflated over the years of getting re-told!

☆ A good dog with great genes - 1920s Alaska sled-relay hero Balto
▼ + stars: | 2023-04-27 | by ( Will Dunham | ) www.reuters.com time to read: +4 min

Cleveland Museum of Natural History/Handout via REUTERS. Balto was feted as a hero, the subject of books and movies, and the dog's taxidermy mount still stands on display at the Cleveland Museum of Natural History. Balto, belonging to a population of working sled dogs in Alaska, also was found to have possessed greater genetic diversity and genetic health than modern canine breeds. Sled dogs were the only viable option. Balto was found to share ancestry with modern Siberian huskies and Alaskan sled dogs as well as Greenland sled dogs, Vietnamese village dogs and Tibetan mastiffs, with no discernible wolf ancestry.

☆ Balto: A good dog with great genes
▼ + stars: | 2023-04-27 | by ( Will Dunham | ) www.reuters.com time to read: +4 min

Cleveland Museum of Natural History/Handout via REUTERS. Balto was feted as a hero, the subject of books and movies, and the dog's taxidermy mount still stands on display at the Cleveland Museum of Natural History. Balto, belonging to a population of working sled dogs in Alaska, also was found to have possessed greater genetic diversity and genetic health than modern canine breeds. Balto was found to share ancestry with modern Siberian huskies and Alaskan sled dogs as well as Greenland sled dogs, Vietnamese village dogs and Tibetan mastiffs, with no discernible wolf ancestry. Balto had a body built for strength and not speed, disappointing the breeder, who had the dog neutered.

☆ From Alpacas to Yaks, Mammal DNA Yields Its Secrets
▼ + stars: | 2023-04-27 | by ( Emily Anthes | ) www.nytimes.com time to read: +1 min

A team of Zoonomia researchers has now used a small piece of that taxidermied tissue to learn more about the celebrity sled dog and his canine contemporaries. What can we say about his genome?”Balto, they found, was genetically “healthier” than modern purebred dogs, with more inherited genetic variation and fewer potentially harmful mutations. That finding likely stems from the fact that sled dogs are typically bred for physical performance and may be a mixture of breeds. Balto also had an assortment of genetic variants that were not present in wolves and were rare or missing in modern purebred dogs, the researchers found. Many variants were in genes involved in tissue development and may have affected a variety of traits important for sled dogs, such as skin thickness and joint formation.

☆ Humans can't live forever, but we haven't even come close to the limit for how long our bodies could last
▼ + stars: | 2023-04-19 | by ( Emily Swaim | ) www.businessinsider.com time to read: +10 min

Mysteries like cellular senescence, telomere length, and DNA methylation hold the keys to our longevity. But so far, no one has figured out how to completely prevent or eliminate harmful senescent cells. DNA methylation is linked to several age-related diseasesTreating or preventing age-related diseases is one of the keys to unlocking longer, healthier lives. Similar to telomeres, DNA methylation is another way scientists can measure your biological age to help predict your life expectancy. For example, telomere shortening can lead to DNA damage, which in turn disrupts your mitochondria.

☆ How to Tell Biotech’s Likely Winners From Losers
▼ + stars: | 2023-04-18 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Photo: ARIANA DREHSLER for The Wall Street JournalJust a handful of biotech companies have approved products and growing sales. Merck ’s $10.8 billion acquisition of Prometheus Biosciences, which is developing a promising treatment for inflammatory bowel disease, is giving the entire biotech sector a lift. On Monday, the SPDR S&P Biotech ETF, which has underperformed other growth sectors this year, closed up 4.7%. For the year, the Biotech fund is down 1.4% versus the Nasdaq-100’s gain of 20%.

Search resuls for: "BioSciences"

25 mentions found